A TIR Domain Variant of MyD88 Adapter-like (Mal)/TIRAP Results in Loss of MyD88 Binding and Reduced TLR2/TLR4 Signaling*

Kamalpreet Nagpal, Theo S. Plantinga, Joyce Wong, Brian G. Monks, Nicholas J. Gay, Mihai G. Netea, Katherine A. Fitzgerald, and Douglas T. Golenbock

Received for publication, April 29, 2009, and in revised form, May 29, 2009. Published, JBC Papers in Press, June 9, 2009, DOI 10.1074/jbc.M109.014886

The adapter protein MyD88 adapter-like (Mal), encoded by TIR-domain containing adapter protein (Tirap) (MIM 606252), is the most polymorphic of the five adapter proteins involved in Toll-like receptor signaling, harboring eight non-synonymous single nucleotide polymorphisms in its coding region. We screened reported mutations of Mal for activity in reporter assays to test the hypothesis that variants of Mal existed with impaired cytokine production and NF-κB activation. A TIR domain variant, Mal D96N (rs8177400), was found to be inactive. In reconstituted cell lines, Mal D96N acted as a hypomorphic mutation, with impaired NF-κB activation upon lipopolysaccharide or PAM3CSK4 stimulation. Moreover, co-immunoprecipitation studies revealed that Mal D96N is unable to interact with MyD88, a prerequisite for downstream signaling to occur. Computer modeling data suggested that residue 96 resides in the MyD88 binding site, further supporting these findings. Genotyping of Mal D96N in three different cohorts suggested that it is a rare mutation. We, thus, describe a rare variant in Mal that exerts its effect via its inability to bind MyD88.

The adapter protein Mal/TIRAP (hereafter referred to as Mal) is involved in the MyD88-dependent pathway downstream of TLR2 and TLR4 (3, 4). It acts as a bridging adapter between the receptor and the sorting adapter MyD88 (5). Upon activation of TLR2 or TLR4, a signaling cascade is initiated which leads to the activation of transcription factors such as nuclear factor-κB (NF-κB), interferon regulatory factor 5 (IRF5), and activator protein (AP-1), ultimately culminating in the production of pro-inflammatory cytokines (6).

The importance of single nucleotide polymorphisms (SNPs) in TLR-related proteins and their association with various infectious and inflammatory diseases have recently emerged (7, 8). Notable among them is a study by Khor et al. (9), who reported that individuals heterozygous for the polymorphism S180L in Mal are protected against pneumococcal disease, bacteremia, malaria, and tuberculosis (9). Within the coding region of a gene, SNPs can alter the characteristics and affect the ability of a protein to function (10). Interestingly, Mal is the most polymorphic of all adapter proteins, harboring at least eight non-synonymous variants in its coding region. It, thus, appears to be an important candidate for studying genetic variation in relation to TLR2 and TLR4 signaling.

In the present study we characterized the known polymorphisms in the coding region of Mal for effects on the function of Mal. We report that one of the mutations in the TIR domain of Mal, D96N, is broadly defective in TLR2 and the MyD88 branch of the TLR4 signaling pathway. We show by biochemical and computer modeling data that the basis of this abnormality is the inability of Mal D96N to bind MyD88. Although the incidence of this lesion in humans is not known, we screened three small populations for the defect and found a single heterozygous individual, suggesting that D96N is a rare mutation. We, thus, identify a mutation in Mal that causes a structural change, affecting the ability of the protein to bind the downstream effector MyD88.

EXPERIMENTAL PROCEDURES

Plasmids and Site-directed Mutagenesis—Most of the constructs described in this work have been described elsewhere. These include pEF-BOS-Mal-FLAG (11), pCDNA3-MyD88CFP (12), pCMV-IRF5-FLAG (13), NF-κB-luciferase, interferon-stimulated response element (ISRE)-luciferase, and Renilla-lu-

---

* This work was supported, in whole or in part, by National Institutes of Health Grants AI52455 and GM54060 (to D. T. G. and K. N.) and AI067497 (to K. A. F.).

† The on-line version of this article (available at http://www.jbc.org) contains supplemental Fig. S1.

1 Supported by a Christ’s College fellowship.
2 Supported by the Wellcome Trust.
3 Supported by a Vidi grant of the Netherlands Organization for Scientific Research.
4 To whom correspondence should be addressed: Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, the Department of Medicine and Nijmegen Institute for Infection, Inflammation, and Immunity, Radboud University Nijmegen Medical Center, 6500 HD Nijmegen, The Netherlands, and the Department of Biochemistry, University of Cambridge, Cambridge CB2 1TN, United Kingdom.
ciferase (14), and the retroviral vector pMSCV2.2-IRES-GFP (15). pEF-BOS-Mal-FLAG and pMSCV2.2-IRES-GFP-human-Mal with the different mutations in the TIRap gene were generated by using a site-directed mutagenesis QuickChange kit (Stratagene) per the manufacturer’s instructions.

Reconstitution of Immortalized Mal Knock-out Macrophages—The immortalized Mal-deficient macrophage-like cell lines was transduced with the retrovirus MSCV2.2. Equal expression of Mal or the Mal variants in selected clones was confirmed by Western blotting with anti-FLAG antibody. A Mal antibody (a gift from S. Akira (16)) was used to compare the expression of endogenous protein in wild type cells with that of the transduced cell lines.

Luciferase Reporter Assay—HEK293T cells were seeded into 96-well plates at a density of 20,000 cells per well and transfected 16 h later with 40 ng of the indicated luciferase reporter genes and the indicated amounts of Mal (WT or polymorphic) using GeneJuice (EMD Biosciences, San Diego, CA). In the case of Fig. 1B, IRF5 construct (10 ng) was co-transfected. The thymidine kinase Renilla-luciferase reporter was co-transfected (40 ng) to normalize the data for transfection efficiency. Two days later reporter gene activity was measured using the Dual Luciferase assay system (Promega).

Enzyme-linked Immunosorbent Assay—Cells were seeded into 96-well plates at a density of 20,000 cells per well and stimulated overnight with the indicated concentrations of the TLR ligands. Cell culture supernatants were assayed for TNFα with enzyme-linked immunosorbent assay kits from R&D systems, according to the manufacturer’s instructions.

Quantitative Real-time PCR—Wild type, Mal-deficient, or D96N-expressing macrophages were plated at a density of 2 × 10⁴ cells per well in a 6-well plate. They were stimulated for 100 ng/ml LPS for 2 h. RNA extraction and IFN-β mRNA induction analysis by quantitative Real-time PCR was carried out as described elsewhere (17).

IKB Degradation Assay—2 × 10⁶ cells were seeded per well into a 6-well plate. After 24 h the cells were treated with 10 nM PAM3CSK4 or 100 ng/ml LPS for the indicated time intervals. Cell lysates were made and run on an 8–16% SDS gel (NuSep), transferred to nitrocellulose membrane, and probed with anti-IKB. (Cell Signaling Technology).

Immunoprecipitations and Immunoblots—HEK293T cells were transfected with TLR2-YFP, TLR4-CFP, or MyD88-CFP and FLAG-tagged Mal (WT or D96N). Two days post-transfection, cells were harvested, and the lysates were incubated overnight with polyclonal anti-FLAG antibody (Invitrogen) and poly-A-Sepharose beads. Rabbit IgG was used as a control. The processed samples were run on an SDS gel, transferred to nitrocellulose membrane, and probed with a horseradish peroxidase-conjugated anti-FLAG antibody (Sigma, MO, USA). The immunoprecipitation of TLR2-YFP, TLR4-CFP and MyD88-CFP was checked by immunoblotting the same membrane with monoclonal anti-GFP antibody (Invitrogen, CA, USA). Expression level of the proteins in whole cell lysates was checked by immunoblotting with horseradish peroxidase-conjugated anti-FLAG antibody and monoclonal anti-GFP antibody.

Molecular Modeling of Mal D96N—The amino acid sequences and three-dimensional structures of the TIR domains of TLR1 and TLR2, homologous proteins used as templates for comparative modeling, were obtained from the Protein Data Bank. Initial alignments between Mal and its templates were obtained using the program FUGUE (18). Models were produced using the program MODELLER (19) as previously described (20). Site-directed Mutator (21) was used to calculate a stability score for a specific point mutation (96N) in the Mal TIR model. Three-dimensional structure visualization and image generation was carried out using PyMol (38).

Genotyping of TIRAP D96N in Human Subjects—Genetic studies were approved by the Ethical Committee of the Radboud University Nijmegen, The Netherlands. Genomic DNA from 91 African Tanzanians, 97 Chinese Han, and 188 Caucasian Dutch individuals (22) were screened for the presence of TIRAP D96N (which encodes for Mal D96N). Screening was performed by PCR amplification and sequencing. For amplification, the forward primer 5’-AGTGAGGGGCACCTGGTAAA-3’ and the reverse primer 5’-CACAGCTCGGACACATTAGCGCC-3’ were used. Sequencing was performed with the same primers on a 3730 DNA Analyzer (Applied Biosystems, Foster City, CA) by the DNA Sequencing Facility, Radboud University.

RESULTS

Transient Expression of D96N Does Not Activate NF-κB and ISRE Reporters—The non-synonymous SNPs occurring in the coding region of human Mal were selected from the NCBI SNP data base. These were examined for their ability to drive two signaling pathways known to function downstream of Mal. Transient expression of WT Mal in HEK293T cells triggers activation of NF-κB- and IRF5-dependent ISRE luciferase reporters (23, 24). Notably, IRF5 is activated downstream of Mal and MyD88 but not TRIF or TRAM (24). As expected, WT Mal could drive both reporters. Moreover, four of the five polymorphisms screened were comparable to wild type Mal in their ability to drive both reporters (Fig. 1, A and B). However, Mal D96N was severely compromised in driving either the NF-κB or the IRF5-ISRE reporter. IRF5 by itself can weakly activate the ISRE reporter, but the co-expression of wild type Mal leads to a much greater activation above this background value (Fig. 1B). In the case of Mal D96N, this increase in activity over the background level was not seen. These results suggest that Mal D96N does not drive signal transduction upon overexpression.

The Expression of WT Mal Functionally Complements Mal-deficient Macrophages—To study these polymorphisms in phagocytes with a clean genetic background, we immortalized bone marrow-derived macrophages from wild type and Mal-deficient mice using a retrovirus encoding several oncogenes (15, 25). These cell lines behave similar to their respective primary bone marrow-derived macrophages (supplemental Fig. S1). We generated retroviruses expressing FLAG-tagged wild type Mal in tandem with an internal ribosomal entry site (IRES)-encoded green fluorescent protein (GFP). This construct expresses a bicistronic mRNA that allows the translation of both Mal and GFP in the Mal-deficient immortalized cell line. The transduced cells were sorted for GFP and then cloned by limiting dilution. In Mal-deficient macrophages, TNFα production in response to LPS was significantly reduced, whereas...
Human Mal carrying the D96N mutation is unable to activate either NF-κB or IRF5. HEK293T cells were transfected with different variants of Mal and either NF-κB luciferase (A) or IRF5 and ISRE-luciferase reporters (B). 48 h post-transfection, lysates were analyzed for luciferase activity. Renilla-luciferase activity was used to normalize for transfection efficiency. Results are reported as the mean of triplicate determinations ± S.D. Each graph is representative of three (A) or two (B) independent experiments. RLUs, relative luciferase units.

**FIGURE 1.** Human Mal carrying the D96N mutation is unable to activate either NF-κB or IRF5. HEK293T cells were transfected with different variants of Mal and either NF-κB luciferase (A) or IRF5 and ISRE-luciferase reporters (B). 48 h post-transfection, lysates were analyzed for luciferase activity. Renilla-luciferase activity was used to normalize for transfection efficiency. Results are reported as the mean of triplicate determinations ± S.D. Each graph is representative of three (A) or two (B) independent experiments. RLUs, relative luciferase units.

Mal Variant Affects MyD88 Binding

Mal D96N Has Impaired Cytokine Production—Reconstituted cell lines were stimulated with LPS and PAM3CSK4, and the pro-inflammatory cytokine TNFα was measured in cell supernatants by enzyme-linked immunosorbent assay. The variants A9P, R13W, S180L, and V197I were fully functional and produced comparable levels of TNFα as WT cells. However, in agreement with our earlier experiments, D96N was significantly compromised in its ability to produce pro-inflammatory cytokines upon stimulation (Fig. 2C). The production of another proinflammatory cytokine, interleukin-6, was similar to TNFα (data not shown). As a control, TNFα production by the double-stranded RNA mimetic poly I:C stimulation was also measured. Poly(I:C) is a TLR3 ligand whose signaling is independent of Mal (26). In this case, TNFα production in cells expressing the D96N mutation was comparable with WT macrophages as well as to cells expressing the different variants of Mal. To test whether the MyD88-independent TLR4 signaling is intact in D96N-expressing cells, we measured induction of IFN-β mRNA upon LPS stimulation using real-time PCR (Fig. 2D). D96N expressing macrophages induced comparable amounts of IFN-β mRNA as WT and Mal-deficient cells. Thus, macrophages expressing the D96N variant of Mal are defective in signaling through TLR2 and the MyD88 branch of TLR4, whereas signaling initiated through other TLRs occurs normally.

IkB Degradation Assays—NF-κB is the predominant transcription factor responsible for pro-inflammatory cytokine production downstream of TLR2- and MyD88-dependent TLR4-signaling pathways. We, therefore, examined the activation of NF-κB (via IkB degradation) after LPS and PAM3CSK4 treatment in the reconstituted cell lines mentioned above. In Mal-deficient macrophages, IkB degradation is abrogated upon PAM3CSK4 treatment, whereas for LPS stimulation Mal-deficient macrophages undergo delayed degradation (27). In WT bone marrow-derived macrophages, IkB was completely degraded at 10 min after LPS or PAM3CSK4 treatment (Fig. 3, row A). As expected, Mal-deficient bone marrow-derived macrophages had a delayed degradation profile in the case of LPS (Fig. 3, left panel, row B) and exhibited no degradation in the case of PAM3CSK4 treatment (Fig. 3, right panel, row B). Immortalized wild type and Mal-deficient cell lines mimicked their primary cell types (Fig. 3, rows C and D). Mal-deficient cell lines expressing wild type Mal, A9P, R13W, S180L, or V197I degraded IkB at 10 min, like the wild type immortalized cells (Fig. 3, rows E–G, I, and J). In contrast, however, and in agreement with the cytokine data, cells expressing the D96N mutant behaved like the Mal-deficient cells (Fig. 3, row H), with no degradation in the case of PAM3CSK4 and a delayed degradation profile after LPS treatment. Glyceraldehyde-3-phosphate dehydrogenase was used as an internal loading control. Thus, Mal D96N is a hypomorphic, if not a null variant of Mal, fully defective in NF-κB activation.

Interaction Studies with TLR4, TLR2, and MyD88—Having established the failure of Mal D96N to signal, we next sought an explanation for the inability of D96N to transduce the signal downstream of TLR2 and TLR4. It is thought that Mal acts as a bridging adapter between the receptor (TLR2 or TLR4) and MyD88 and, thus, physically interacts with both (28). We, therefore, examined whether the D96N mutation affected the ability of Mal to interact with TLR2, TLR4, or MyD88. Transient transfections in HEK293T cells followed by immunoprecipitation assays were carried out to address this question (Fig. 4). As expected, wild type Mal interacted with the receptors TLR2 (Fig. 4A) and TLR4 (Fig. 4B) and with MyD88 (Fig. 4C, lane 6). Like wild type Mal, D96N could be co-immunoprecipitated with both TLR2 and TLR4, indicating that this mutation does not affect the ability of Mal to interact with either of these receptors. However, D96N was severely compromised in its ability to interact with MyD88. Although wild type Mal could co-immunoprecipitate with MyD88, D96N could not (Fig. 4C, lane 7). Thus, the hypomorphic phenotype of D96N appeared to result from its inability to interact with MyD88.

Modeling Studies for Mal Suggest That a Change in Surface Charge Accounts for the D96N Phenotype—We generated high quality models of the TIR domains of both WT and D96N Mal using the resolved crystal structures of TLR1 and -2 as templates (29). The Mal TIR domain was predicted to have good geometry, with none of its ψ-ϕ dihedral angles within the disallowed regions of a Ramachandran plot and 90.6% in geometrically favored regions. JOY and Verify3D outputs (20) revealed
that the environment of residues in the model of Mal are similar to those of the TLR1 and TLR2 TIR domains used as templates and were not energetically unfavorable. Residue Asp-96 was predicted to lie on the surface of the TIR domain in a highly negatively charged region. Mal D96N was modeled using the same approach as the wild type protein and exhibited no significant changes in structure or geometry compared with wild type Mal. However, one individual in the Caucasian Dutch cohort was heterozygous for the D96N mutation. Although this experiment is not an exhaustive assessment of the frequency of MalD96N in all populations, we can conclude that this variation of Mal has a very low prevalence in the general population. We sequenced MalD96N in one African Tanzanian (n = 97), Chinese Han (n = 91), and Caucasian Dutch (n = 188) individuals. The African Tanzanian and the Chinese individuals all apparently expressed wild type Mal. However, one individual in the Caucasian Dutch cohort was heterozygous for the D96N mutation. Although this experiment is not an exhaustive assessment of the frequency of MalD96N in all populations, we can conclude that this variation of Mal has a very low prevalence in the populations studied. This is understandable given the strong phenotype in innate signaling that we observed in our experiments. Indeed, individuals homozygous for MalD96N would be expected to have a phenotype similar to the strong phenotype in innate signaling that we observed in our experiments.
DISCUSSION

TLRs are the key sensors of microbial infection in mammals. Upon encountering a pathogen, they elicit an inflammatory response involving an intricate network of signaling molecules. Changes in the structure of the TLR signaling components can have dramatic effects on the outcome of various infectious diseases. Some of these changes may be caused by the presence of a SNP in the coding region of the protein. The effects of SNPs on the structure of proteins and the consequent effect on TLR signaling have been described in many studies (32–35).

TIR domain interactions between the TLR components are a necessary event for downstream signaling to occur. SNPs in adapter proteins could, thus, be influential in determining the progression of infection. Incidentally, Mal is the most polymorphic of all the adapter proteins. Of the eight known coding polymorphisms in Mal, only one, S180L, has been previously described (9). Khor et al. (9) found that the heterozygotes carrying this polymorphism were protected from malaria, tuberculosis, and bacteremia. In view of these observations we hypothesized that SNPs in Mal could affect TLR2 and TLR4 signaling.

The data presented herein make a strong case that a variant of Mal, D96N, is essentially nonfunctional. Our model would predict that SNPs in Mal could affect TLR2 and TLR4 but is unable to bind MyD88. Hence, this characterization of a natural Mal mutant identifies with apparent pinpoint precision a single residue in the TIR domain of Mal that is critical for its interaction with MyD88.

The frequency of D96N in the populations we analyzed was very low. In the initial screen we genotyped individuals from three different populations. However, we found just one individual (of 376) who was heterozygous for D96N. Considering the deleterious phenotype we observe, the low frequency of this polymorphism is not unexpected. As the mutation exists, it is nearly certain that there are sporadic individuals born who are

![FIGURE 3. Mal D96N fails to degrade kB-κ effectively. NF-κB activation in the reconstituted cell lines was examined via kB-κ degradation assay. The cells were stimulated with LPS (left panel) or PAM2CSK4 (right panel) for the indicated time points, and the whole cell lysates loaded on a denaturing gel, transferred to nitrocellulose membrane, and blotted with kB-κ antibody. Levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) act as an internal loading control. WT, wild type; ko, knock out; WB, Western blot.](image-url)
homozygous for D96N. Because the data suggest the failure to bind MyD88 is the reason for the phenotype of D96N, we believe that individuals carrying this mutation in a homozygous state would be extremely susceptible to both Gram-negative and Gram-positive infections. In view of the reported serious clinical significance of MyD88 and IRAK4 deficiencies, two gene products that are downstream of Mal and which should be similar to Mal D96N expression, we believe that Mal D96N represents a rare, potentially life-threatening mutation (36, 37). Indeed, individuals occasionally present for medical case with sepsis in the absence of any known risk factors; we would suggest that MalD96N should be considered under such circumstances as a potential cause of such a clinical presentation.

In contrast to what one might expect for the rare individual with two mutant alleles, the fact that this amino acid variant exists in the population, albeit at a very low frequency, suggests that heterozygous individuals have a survival advantage under some, but still undefined, circumstances. The key to determining the nature of this hypothetical heterozygous advantage is to analyze enough individuals from enough different populations to define clinical correlates.

Acknowledgment—We thank Dr. Shizuo Akira for the gift of anti-Mal/TIRAP antiserum and sharing of the Tirap knockout mice.

REFERENCES
1. O’Neill, L. A. (2008) Immunity 29, 12–20
2. Hong-Geller, E., Chaudhary, A., and Lauer, S. (2008) Curr. Drug Discov. Technol. 5, 29–38
